A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious and potentially...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Results from AMGEN’S Phase 2 Obesity Study OF Monthly MariTide Presented at The American Diabetes Association 85th Scientific Sessions MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau,...
Administration Moves Forward with NIH Funding Cuts, Restructuring On Friday, May 2, the White House released the president’s budget request for Fiscal Year 2026 (FY26). As is typical in the first year of a presidential term, the budget lacks many details, and so it is informally referred to as a “skinny budget.” The budget outlines...
As experts dedicated to providing patients with compassionate, evidence-based care every day, we are disappointed in the United States v. Skrmetti decision, which increases the likelihood that other states will limit or eliminate families’ and patients’ ability to access medical care. As doctors, nurse practitioners, and nurses, we believe that every patient is different. Decisions...
Endocrinology’s brightest minds will gather once again in San Francisco from July 12–15 for ENDO 2025. Showcasing groundbreaking research, cutting-edge clinical advances, and abstract discussions on the future of hormone science and care, our signature conference promises a transformative experience for researchers, clinicians, and healthcare leaders alike. While San Francisco sets the stage for ENDO...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * MiniMed to be Metronic’s New Diabetes Company On June 12, Medtronic plc announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company’s roots, reflecting its original name prior to its acquisition by...
A new study from the Avon Longitudinal Study of Parents and Children (ALSPAC) is challenging long-held assumptions about how we measure overweight and obesity in children. According to findings published in Obesity and Endocrinology in January 2025, body mass index (BMI) — the most commonly used tool for assessing weight status — may dramatically overestimate...
Endocrine Society champions resolution passed by House of Delegates On June 10, the American Medical Association (AMA) House of Delegates passed the Endocrine Society’s resolution to improve access to anti-obesity medications. In the resolution, the AMA committed to advocating for reducing the burden of prior authorization, when healthcare providers must seek insurance plan approval before...
Administration Moves Forward with NIH Funding Cuts, Restructuring On Friday, May 2, the White House released the president’s budget request for Fiscal Year 2026 (FY26). As is typical in the first year of a presidential term, the budget lacks many details, and so it is informally referred to as a “skinny budget.” The budget outlines...
